Sanofi/Regeneron’s Alirocumab Cuts CV Events And Cholesterol
This article was originally published in The Pink Sheet Daily
A preliminary ad hoc analysis suggests alirocumab has beneficial effects on patient outcomes as well as markedly reducing LDL-cholesterol levels in patients with hypercholesterolemia already treated with maximum doses of statins.
You may also be interested in...
Alirocumab was associated with lower rate of major cardiovascular events compared to placebo in post-hoc, interim Phase III analysis – boosting chances for FDA approval in 2015. The firm is taking no chances on review period, purchasing a priority review voucher from BioMarin.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.